上半年药企业绩报告:创新药成增长主力国际化仍待突破

动脉网
Aug 26

2025年上半年,多家上市药企的业绩报告显示,创新药业务已成为企业增长的核心驱动力。恒瑞医药、翰森制药、远大医药和先声药业等公司的创新药收入占比显著提升,部分公司甚至超过50%。尽管传统仿制药业务因集采政策承压,但创新药销售及对外授权收入推动了业绩回暖。这些药企在研发投入上持续加大,例如恒瑞医药上半年研发投入达38.71亿元,累计研发投入超480亿元;先声药业的研发投入率高达28.7%,过去十年...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10